Breaking News Instant updates and real-time market news.

PETQ

PetIQ

$31.27

-1.77 (-5.36%)

, MTSI

Macom

$15.17

0.28 (1.88%)

19:01
11/13/18
11/13
19:01
11/13/18
19:01

Fly Intel: After Hours Movers

UP AFTER EARNINGS: PetIQ (PETQ) up 7.1%... MACOM Technology Solutions (MTSI) up 7.0%... SVMK Inc. (SVMK) up 6.3%... Resideo Technologies (REZI) up 3.4%... Laureate Education (LAUR) up 2.1%... Varex Imaging Corp (VREX) up 1.2%... SVB Financial (SIVB) up 1.0%. ALSO HIGHER: Cloud Peak Energy (CLD) up 7.5% after announcing review of strategic alternatives... Etsy (ETSY) up 2.3% after being initiated with a Buy at BTIG... 3M (MMM) up 1.8% after announcing new $10B stock buyback... Eagle Bancorp (EGBN) up 1.4% after announcement it will enter S&P SmallCap 600 index... Golden Entertaintment (GDEN) up 1.3% after announcing CFO stock purchase... Akebia Therapeutics (AKBA) up 0.9% after board recommended vote in favor of Keryx merger. DOWN AFTER EARNINGS: Amirys (AMRS) down 31.9%... Quest Resource Holding Corp (QRHC) down 7.1%... Switch (SWCH) down 6.1%... Wix.com (WIX) down 4.7%... Tilray (TLRY) down 2.2%... Blue Apron (APRN) down 1.6%. ALSO LOWER: Resonant (RESN) down 11.8% after equity offering... CareDX (CDNA) down 2.9% after equity offering... Ladder Capital (LADR) down 1.5% after equity offering... Consolidated Edison (ED) down 0.8% after equity offering.

PETQ

PetIQ

$31.27

-1.77 (-5.36%)

MTSI

Macom

$15.17

0.28 (1.88%)

SVMK

SurveyMonkey

$11.33

-0.185 (-1.61%)

REZI

Resideo

$21.28

-0.06 (-0.28%)

LAUR

Laureate Education

$15.53

-0.41 (-2.57%)

VREX

Varex Imaging

$26.11

-0.65 (-2.43%)

SIVB

SVB Financial

$242.68

1.84 (0.76%)

CLD

Cloud Peak

$1.32

-0.12 (-8.33%)

ETSY

Etsy

$47.31

-3.33 (-6.58%)

MMM

3M

$198.40

1.31 (0.66%)

EGBN

Eagle Bancorp

$49.19

0.48 (0.99%)

GDEN

Golden Entertainment

$14.32

-0.46 (-3.11%)

AKBA

Akebia

$7.76

0.04 (0.52%)

AMRS

Amyris

$5.90

0.04 (0.68%)

QRHC

Quest Resource

$2.23

-0.01 (-0.45%)

SWCH

Switch

$9.27

-0.075 (-0.80%)

WIX

Wix.com

$91.30

2.83 (3.20%)

TLRY

Tilray

$111.25

-1.95 (-1.72%)

APRN

Blue Apron

$1.22

-0.03 (-2.40%)

RESN

Resonant

$2.88

-0.03 (-1.03%)

CDNA

CareDx

$25.49

-2.01 (-7.31%)

LADR

Ladder Capital

$17.58

-0.03 (-0.17%)

ED

Consolidated Edison

$79.14

0.48 (0.61%)

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 15

    Nov

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 04

    Dec

  • 11

    Dec

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 16

    Nov

PETQ PetIQ
$31.27

-1.77 (-5.36%)

09/28/18
KING
09/28/18
INITIATION
Target $49
KING
Buy
PetIQ initiated with a Buy at CL King
CL King analyst David Westenberg initiated PetIQ with a Buy and $49 price target.
07/02/18
JEFF
07/02/18
NO CHANGE
Target $32
JEFF
Buy
Jefferies remains bullish on PetIQ, boosts price target to $32
Jefferies analyst Kevin Grundy raised his price target for PetIQ (PETQ) to $32 from $30 following a Walmart (WMT) store visit to a new VetIQ Petcare clinic in Lehighton, PA. The analyst sees see PetIQ's retail strategy as sensible given the high margin/return profile of the model. He believes the company's clinic rollout is on track and remains bullish on the stock with a Buy rating.
08/15/18
RHCO
08/15/18
NO CHANGE
Target $40
RHCO
Buy
PetIQ price target raised to $40 from $30 at SunTrust
SunTrust analyst William Chappell raised his price target on PetIQ to $40 and kept his Buy rating after its Q2 sales beat and raised FY18 guidance. The analyst notes that the investment story for the company now hinges on the wellness center rollout and expects to hear an update on those developments in the coming months.
10/05/18
OPCO
10/05/18
NO CHANGE
Target $50
OPCO
Outperform
PetIQ price target raised to $50 from $28 at Oppenheimer
Oppenheimer analyst Brian Nagel reiterated an Outperform rating on PetIQ and raised his price target to $50 from $28. In a research note to investors, Nagel says PetIQ's "unique" business model continues to take shape well and the market is still meaningfully under-appreciating the company's longer-term sales and profit potential. He also contends that the acquisition of VIP Petcare not only affords the chain a new, higher margin revenue stream, but also serves to meaningfully strengthen its core distribution business.
MTSI Macom
$15.17

0.28 (1.88%)

09/12/18
STFL
09/12/18
DOWNGRADE
Target $20
STFL
Sell
Macom downgraded to Sell at Stifel on cycle peak, debt concerns
As previously reported, Stifel analyst Tore Svanberg downgraded Macom to Sell from Hold, arguing that multiple recent industry data points seem to suggest the analog and mixed-signal semiconductor markets are peaking. Amid the potentially peaking semi cycle, Svanberg is concerned that rising interest rates raise the risk for debt-heavy firms, which is how he identifies Macom. Svanberg cut his price target on Macom shares to $20 from $22.
09/12/18
STFL
09/12/18
DOWNGRADE
STFL
Sell
Macom downgraded to Sell from Hold at Stifel
09/12/18
09/12/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. GOLDMAN CUTS MICRON TO NEUTRAL: Goldman Sachs analyst Mark Delaney downgraded Micron Technology (MU) to Neutral from Buy and lowered his price target for the shares to $50 from $68. The analyst, who is not making a call on the upcoming fiscal Q4 results on September 20, sees weaker fundamentals for DRAM and NAND in calendar Q4 and the first half of 2019. Delaney expects Micron's gross margin to decline sequentially from Q4 of 2018 through mid-2019, and he notes that the stock is historically well correlated with the company's gross margin. His view of margin declines is due to lower memory average selling prices, both from more "challenging" DRAM conditions and also NAND oversupply. Micron is down 5.8% in late morning trading. GOLDMAN CUTS LAM RESEARCH TO NEUTRAL: Goldman Sachs analyst Toshiya Hari downgraded Lam Research (LRCX) to Neutral and lowered his price target for the shares to $180 from $224. The analyst also lowered his coverage view on the Semiconductor Capital Equipment space to Neutral from Attractive. Hari reduced his 2018/2019 memory capex expectations following "early signs of excess supply" in DRAM combined with further weakness in NAND pricing. STIFEL CUTS NXP SEMI, OTHER SEMI COS: Stifel analyst Tore Svanberg downgraded NXP Semiconductors (NXPI) to Sell from Hold, arguing that multiple recent industry data points seem to suggest the analog and mixed-signal semiconductor markets are peaking. He is particularly concerned, given the peaking industry condition, that rising interest rates raise the risk for debt-heavy firms, he added. Svanberg cut his price target on NXP shares to $84 from $99. Svanberg also downgraded Macom (MTSI) to Sell, and Power Integrations (POWI) and Maxim Integrated (MXIM) to Hold. ANALYSTS NEGATIVE ON SNAP: BTIG analyst Richard Greenfield downgraded Snap (SNAP) to Sell from Neutral with a price target of $5, saying his previous assumption that "communications apps were sticky and would protect engagement" was incorrect. The analyst notes that while he waited for "management to figure out monetization", the stock has lost over half of its value. Greenfield believes that the pain is likely not over, stating that he is now "tired" of the company's excuses for missing numbers and adding that the anticipated product innovation ability of CEO Spiegel has been disappointing. Additionally, Citi analyst Mark May lowered his price target for Snap to $8 after removing his takeover premium assumption. The analyst had assumed a 50% probability of a takeout at a 35% premium to his fundamental value of $8 per share. However, he now sees less likelihood of a near-term takeover due to Snap's recent operational challenges. The analyst kept a Sell rating on the shares.
10/18/18
STFL
10/18/18
NO CHANGE
STFL
Stifel lowers analog and IoT semiconductor estimates on broad-based slowdown
Stifel analyst Tore Svanberg said he expects Q3 to come in essentially in line with expectations for analog and IoT semiconductor companies, but sees their Q4 outlooks being impacted by a potential supply-chain correction or slower end-market growth. He now believes 2019 will now be a down year, projecting a 2%-4% contraction, and sees companies aligned with strong secular growth stories as poised to outperform their peers. Svanberg identifies Monolithic Power (MPWR), Silicon Labs (SLAB), Semtech (SMTC) and Quantenna (QTNA) as among the companies he sees being aligned with strong secular growth stories. In conjunction with the sector preview, Svanberg lowered his price targets on Monolithic Power, Silicon Labs, Alpha & Omega (AOSL), Macom (MTSI), Maxim Integrated (MXIM), MaxLinear (MXL), NXP Semiconductors (NXPI), O2Micro (OIIM), Power Integrations (POWI) and Texas Instruments (TXN).
SVMK SurveyMonkey
$11.33

-0.185 (-1.61%)

11/13/18
WELS
11/13/18
INITIATION
Target $13
WELS
Market Perform
SurveyMonkey initiated with a Market Perform at Wells Fargo
Wells Fargo analyst Ivy Cong started SurveyMonkey with a Market Perform rating and $13 price target. As an established category leader from an efficient self-serve revenue model to a growth story driven by expanding enterprise sales, SurveyMonkey makes for a compelling investment case, he contends. However, the analyst believes that these factors are adequately priced into the current share price, especially considering the company's below-average revenue growth versus SaaS peers.
10/22/18
RHCO
10/22/18
INITIATION
Target $16
RHCO
Buy
SurveyMonkey initiated with a Buy at SunTrust
SunTrust analyst Youssef Squali initiated SurveyMonkey (SVMK) with a Buy rating and a price target of $16, saying the company is "effectively leveraging its brand, 'freemium' product, large registered user base and infrastructure to sustainably grow revenues double digits". The analyst expects the company to gain market share in the intelligence business while also citing the visibility of its cash flows from its subscription-based business model. Squali sees further opportunity for growth for SurveyMonkey coming from its enterprise upsell initiative and partnership with Salesforce (CRM).
10/22/18
FBCO
10/22/18
INITIATION
Target $13
FBCO
Neutral
SurveyMonkey initiated with a Neutral at Credit Suisse
Credit Suisse analyst Stephen Ju started SurveyMonkey with a Neutral rating and $13 price target. Given SurveyMonkey's core proposition is to help businesses gather external and internal data to make more informed strategic decisions, the analyst believes it remains a valuable and critical asset. Furthermore, following its investments in 2017 to upgrade its product suite for enterprise consumption, Ju believes it is at only the initial stages of a harvest cycle. That said, with the stock currently trading within 10% of his target price, the analyst is on the sidelines waiting for a more favorable entry point.
10/22/18
10/22/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Domino's Pizza (DPZ) initiated with a Neutral at UBS. 2. Arco Platform (ARCE) initiated with an Overweight at Morgan Stanley, an Outperform at Itau BBA, and a Buy at Goldman Sachs. 3. Arvinas (ARVN) initiated with a Neutral at Goldman Sachs and an Overweight at Piper Jaffray. 4. Ra Medical Systems (RMED) initiated with a Buy at SunTrust as well as an Overweight at Cantor Fitzgerald and Piper Jaffray. 5. SurveyMonkey (SVMK) initiated with a Buy at SunTrust and BofA/Merrill, an Overweight at JPMorgan, and a Neutral at Credit Suisse and UBS. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
REZI Resideo
$21.28

-0.06 (-0.28%)

10/30/18
FBCO
10/30/18
NO CHANGE
Target $158
FBCO
Neutral
Honeywell price target lowered to $158 from $165 at Credit Suisse
Credit Suisse analyst John Walsh lowered his price target for Honeywell (HON) to $158 from $165 after the company completed the spinoff of Resideo Technologies (REZI). The analyst reiterates a Neutral rating on Honeywell's shares.
10/25/18
10/25/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Seadrill (SDRL) initiated with a Buy at BTIG. 2. Resideo (REZI) initiated with an Outperform at Oppenheimer. 3. Magnolia Oil & Gas (MGY) initiated with an Overweight at MUFG. 4. Athenex (ATNX) initiated with a Buy at Ladenburg. 5. Zumiez (ZUMZ) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/24/18
OPCO
10/24/18
INITIATION
Target $35
OPCO
Outperform
Resideo initiated with an Outperform at Oppenheimer
Oppenheimer initiated Resdeo with an Outperform and $35 price target.
LAUR Laureate Education
$15.53

-0.41 (-2.57%)

12/19/17
STFL
12/19/17
NO CHANGE
Target $18
STFL
Buy
Chilean election result a material positive for Laureate Education, says Stifel
Stifel analyst Shlomo Rosenbaum said Chile's election result is a "material positive" for Laureate Education as Sebastian Pinera is less likely to support legislation for free post-secondary education, the prospect of which has weighed on the stock. He maintains a Buy rating and $18 price target on Laureate shares.
12/28/17
BARD
12/28/17
NO CHANGE
Target $16
BARD
Outperform
Laureate Education valuation compelling at current levels, says Baird
Baird analyst Jeffrey Meuler noted Laureate Education announced its fourth divestiture since late November as part of its plans to divest five to seven locations. He believes its current valuation remains compelling as the divestitures are being done at attractive multiples well above their public market value. Meuler sees an improving risk/reward profile and reiterated his Outperform rating and $16 price target on Laureate Education shares.
03/22/18
BRRR
03/22/18
NO CHANGE
BRRR
Laureate Education Q4 results beat expectations, says Barrington
Barrington analyst Alexandar Paris, Jr. said that Laureate Education's Q4 results, both for adjusted EBITDA and total revenue, were above expectations, and noted that the company's guidance for 2018 was reaffirmed. Paris reiterated an Outperform rating and $18 price target, saying shares were attractively valued at current levels.
04/23/18
PIPR
04/23/18
NO CHANGE
Target $20
PIPR
Overweight
Laureate Education risk/reward compelling at current levels, says Piper Jaffray
Enrollment growth, margin upside and balance sheet improvement are the catalysts for Laureate Education shares, Piper Jaffray analyst Peter Appert tells investors in a research note. The analyst expects to see all three in 2018. Further, positive resolution of Chilean uncertainty and elimination of the preferred stock overhang could also serve as catalysts, Appert adds. He finds Laureate's risk/reward as compelling and keeps an Overweight rating on the shares. The analyst upped his price target for the name to $20 from $19.
VREX Varex Imaging
$26.11

-0.65 (-2.43%)

12/21/17
JEFF
12/21/17
NO CHANGE
JEFF
Jefferies lays out top 2018 ideas in Medical Supplies & Devices
Jefferies analyst Raj Denhoy calls Haemonetics (HAE), AxoGen (AXGN), Abbott (ABT) and Hologic (HOLX) his top Medical Supplies & Devices ideas to start 2018. Following a year of strong device performance in 2017, the analyst believes 2018 is "looking like more of the same." Denhoy raised his price target for Abiomed (ABMD) to $220, for Dexcom (DXCM) to $70, for Haemonetics to $68, for Hologic to $52, for LivaNova (LIVN) to $94, for Varex Imaging (VREX) to $44 and for Zimmer Biomet (ZBH) to $140. The analyst has Buy ratings on all of those stocks.
04/19/18
SIDC
04/19/18
INITIATION
SIDC
Neutral
Varex Imaging initiated with a Neutral at Sidoti
09/14/18
JPMS
09/14/18
INITIATION
Target $30
JPMS
Neutral
Varex Imaging assumed with a Neutral at JPMorgan
JPMorgan analyst Mark Strouse assumed coverage of Varex Imaging with a Neutral rating and $30 price target. The rating is unchanged from the firm's prior coverage. The analyst believes the stock will likely remain volatile until the company's execution improves.
08/03/18
JEFF
08/03/18
NO CHANGE
Target $33
JEFF
Buy
Varex Imaging price target lowered to $33 from $40 at Jefferies
Jefferies analyst Anthony Petrone lowered his price target for Varex Imaging to $33 after the company missed Q2 expectations and cut its outlook. Orders remained lumpy and are now exacerbated by China retaliatory tariffs, Petrone tells investors in a post-earnings research note. The analyst says future tariffs could present downside to his new estimates but he keeps a Buy rating on Varex Imaging.
SIVB SVB Financial
$242.68

1.84 (0.76%)

08/27/18
JEFF
08/27/18
NO CHANGE
Target $378
JEFF
Buy
SVB Financial price target raised to $378 from $360 at Jefferies
Jefferies analyst Casey Haire raised his price target for SVB Financial to $378 after meeting with management. Management was upbeat about growth prospects, but also cautioned that the Q2 performance was unique due to robust volume of life science initial public offerings and likely unsustainable, Haire tells investors in a research note. However, the IPO market remains strong and SVB is confident that its deposit strategy, which began in March, will be successful, the analyst adds. He keeps a Buy rating on the shares.
10/26/18
DADA
10/26/18
UPGRADE
DADA
Buy
SVB Financial upgraded to Buy from Neutral at DA Davidson
10/29/18
RHCO
10/29/18
NO CHANGE
Target $270
RHCO
Buy
SVB Financial price target lowered to $270 from $350 at SunTrust
SunTrust analyst Jennifer Demba lowered her price target on SVB Financial to $270 to reflect the lower industry valuations as well as the bank's higher expense growth. The analyst also keeps her Buy rating on SVB Financial, noting its position of a "preferred lender for the innovation industries" in spite of the growing competition. Demba contends that even though the stock trades at a premium multiple of 12.7-times forward earnings vs. 10.1-times peer group average, she still sees shares as "attractive".
10/26/18
DADA
10/26/18
UPGRADE
Target $345
DADA
Buy
SVB Financial upgraded to Buy at DA Davidson on growth trends
DA Davidson analyst Gary Tenner upgraded SVB Fianacial to Buy from Neutral and kept his $345 price target. The analyst states that the company's "growth, profitability, and specialty niche" profile make it worthy of a premium multiple thanks to its "dominant position in the tech/innovation sector, growing fee businesses, and untapped international expansion opportunities".
CLD Cloud Peak
$1.32

-0.12 (-8.33%)

03/28/18
JPMS
03/28/18
DOWNGRADE
JPMS
Underweight
Cloud Peak downgraded to Underweight from Neutral at JPMorgan
07/24/18
CLKS
07/24/18
DOWNGRADE
CLKS
Sell
Cloud Peak downgraded to Sell from Neutral at Clarksons Platou
03/29/18
03/29/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. GameStop (GME) downgraded to Underperform from Neutral at BofA/Merrill by analyst Curtis nagle, who said he no longer believes GameStop's non-gaming segments will be sources of growth or earnings over the next few years and cut estimates well below the Street for 2018. He expects increased earnings pressure in 2019 and beyond as strong sales from the Nintendo Switch and Collectibles expansion, and lower tax rate are lapped. 2. Cloud Peak Energy (CLD) downgraded to Underweight from Neutral at JPMorgan by analyst John Bridges, saying he sees higher risk for the company from lower natural gas prices as production ramps up from the Permian basin. He also believes Cloud Peak has a "lesser diversified production profile" with exposure to thermal coal only. 3. Starbucks (SBUX) downgraded to Neutral from Outperform at Wedbush. 4. ViaSat (VSAT) downgraded to Underweight from Equal Weight at Barclays by analyst Mathieu Robilliard. The analyst sees see continued risk for oversupply in the satellite industry. The sector stock price performance has started to reflect these concerns, apart from ViaSat which has outperformed peers, Robilliard said, adding that he believes the current stock price reflects assumptions that are too optimistic. 5. DiamondRock (DRH) downgraded to Underperform from Neutral at Boenning & Scattergood by analyst Floris van Dijkum following share strength related to the LaSalle Hotel (LHO) bid announcement as he believes shares are not overly discounted relative to hotel peers. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/29/18
JPMS
03/29/18
DOWNGRADE
JPMS
Underweight
JPMorgan downgrades Cloud Peak to Underweight on natural gas price risk
JPMorgan analyst John Bridges last night downgraded Cloud Peak Energy to Underweight from Neutral without a price target. The analyst sees higher risk for the company from lower natural gas prices as production ramps up from the Permian basin. He also believes Cloud Peak has a "lesser diversified production profile" with exposure to thermal coal only.
ETSY Etsy
$47.31

-3.33 (-6.58%)

11/07/18
RBCM
11/07/18
NO CHANGE
Target $52
RBCM
Sector Perform
Etsy price target raised to $52 from $45 at RBC Capital
RBC Capital analyst Mark Mahaney raised his price target on Etsy to $52 after its Q3 results showed "strong and improving fundamentals" marked by "growth acceleration and margin expansion". The analyst cites a "robust" gross merchandise sales growth of 20.8% at $923M - above the consensus $914M - along with a net 60K in net Active Seller adds, while also raising his FY19 revenue view to $774M from $764M. Mahaney keeps his Sector Perform rating on Etsy however, noting "competition from a number of fronts, and executional challenges as it ramps in scale".
10/30/18
DADA
10/30/18
NO CHANGE
Target $59
DADA
Buy
Etsy should be bought on a pullback, says DA Davidson
DA Davidson analyst Tom Forte kept his Buy rating and $59 price target on Etsy, saying he is "confident" in its management to increase earnings, doing "more with less", and pursuing all opportunities "big or small". The analyst believes that investors should buy "this gem" on any pullback amid a "secular shift in buyers, especially millennials, who appreciate the ability to know the seller from whom they are purchasing products".
11/13/18
BTIG
11/13/18
INITIATION
Target $59
BTIG
Buy
Etsy initiated with a Buy at BTIG
BTIG analyst Marvin Fong started Etsy with a Buy rating and $59 price target. The analyst is positive on the company's "Amazon-baptized" business model and sees "multiple de-risked growth drivers." He believes investors are underestimating the upside potential of a Etsy's estimated 32M dormant buyers and is bullish on the company's Promoted Listings and International opportunity.
11/06/18
LOOP
11/06/18
NO CHANGE
Target $57
LOOP
Buy
Etsy price target lowered to $57 from $65 at Loop Capital
Loop Capital analyst Laura Champine lowered her price target on Etsy to $57 in spite of its beat on earnings in Q3, citing the company's "conservative guidance" and "elevated marketing expense". The analyst also lowers her FY19 EPS view to 73c from 79c to reflect the higher spending but keeps her Buy rating, anticipating the company's improvements to the buyer experience and marketing investments to "drive buyers' frequency in multiples of the current 1x/year over time".
MMM 3M
$198.40

1.31 (0.66%)

10/24/18
RBCM
10/24/18
NO CHANGE
Target $223
RBCM
Outperform
3M price target lowered to $223 from $234 at RBC Capital
RBC Capital analyst Deane Dray lowered his price target on 3M to $223 after its Q3 earnings miss and another "disappointing" guidance cut for FY18 accompanying the results. The analyst points to the company's "worsening FX, raw materials, and weaker organic growth" headwinds, but adds that he does not believe that a negative macro inflection point has been reached. Dray also keeps his Outperform rating on 3M, saying its risk-reward is attractive with the stock sitting on "meaningful relative P/E support level".
10/12/18
FBCO
10/12/18
INITIATION
FBCO
Outperform
EE, MI Sector initiated with Opportunistic View at Credit Suisse
Credit Suisse analyst John Walsh initiated the U.S. Electrical Equipment and Multi-Industry Sector with an Opportunistic View, telling investors in a research note that he believes at this point in the cycle stock appreciation will be driven by earnings growth and capital allocation. He is most positive on energy-related and non-residential end markets while cautious on Fossil Power markets. Specifically, Walsh initiated Allegion (ALLE), Eaton (ETN), Ingersoll-Rand (IR), Lennox (LII), 3M (MMM) and Xylem (XYL) with Outperform ratings, Acuity Brands (AYI), Emerson (EMR), Flowserve (FLS), Fortiv (FTV), GE (GE), Honeywell (HON) and Johnson Controls (JCI) with Neutral ratings and Rockwell Automation (ROK) with an Underperform rating.
10/12/18
GDHS
10/12/18
INITIATION
Target $228
GDHS
Buy
3M initiated with a Buy at Gordon Haskett
Gordon Haskett analyst John Inch started 3M with a Buy rating and $228 price target.
10/24/18
FBCO
10/24/18
NO CHANGE
Target $222
FBCO
Outperform
3M price target lowered to $222 from $228 at Credit Suisse
Credit Suisse analyst John Walsh lowered his price target for 3M to $222 from $228, while reiterating an Outperform rating on the shares. While the 38c mid-point reduction to guidance was worse than expected, the analyst thinks it sets an achievable base for CEO Mike Roman to build off of going forward.
EGBN Eagle Bancorp
$49.19

0.48 (0.99%)

07/20/18
KBWI
07/20/18
NO CHANGE
Target $65
KBWI
Outperform
Eagle Bancorp selloff post earnings overdone, says Keefe Bruyette
Keefe Bruyette analyst Catherine Mealor views yesterday's post-earnings pullback in shares of Eagle Bancorp as overdone. The analyst lowered her price target for the stock to $65 from $70 and keeps an Outperform rating on the name. While the quarter was in-line, the 168% deposit beta is what drove the stock, Mealor tells investors in a research note. The analyst points out that even with the beta, net interest margin "held the line" at 4.15%, only down two basis points.
01/19/18
SPHN
01/19/18
UPGRADE
Target $69
SPHN
Overweight
Eagle Bancorp upgraded to Overweight from Equal Weight at Stephens
Stephens analyst Austin Nicholas upgraded Eagle Bancorp to Overweight from Equal Weight, as he sees the bank's Q4 beat as evidence that its high-growth, efficient business model is intact. He thinks the stock should trade at a modest premium to Eagle's regional peers and in-line with its high profitability peers. Nicholas set a $69 price target on Eagle Bancorp shares.
12/04/17
SDLR
12/04/17
NO CHANGE
Target $65
SDLR
Buy
Eagle shares pricing in 'enough of the bad news,' says Sandler O'Neill
Sandler O'Neill analyst Casey Whitman believes "enough of the bad news has been baked in" with Eagle Bancorp shares down 25%. Following a short report, the fundamental question is the legality of the actions the bank and the CEO have taken, and the company's press releases seem to address those concerns, Whitman tells investors in a research note. He sees the worst case scenario as the regulators do find a problem and/or the CEO must step down. Whitman has a buy rating on Eagle with a $65 price target.
08/27/18
GABE
08/27/18
INITIATION
Target $74
GABE
Buy
Eagle Bancorp initiated with a Buy at Gabelli
Gabelli analyst Steve Comery initiated Eagle Bancorp with a Buy rating and $74 private market value estimate, stating that he views the recent pullback in the stock as an overreaction to deposit pricing and loan growth concerns. He sees the company's core competencies in commercial lending and noninterest deposits gathering as a sustainable competitive advantage, Comery tells investors.
GDEN Golden Entertainment
$14.32

-0.46 (-3.11%)

09/24/18
JEFF
09/24/18
NO CHANGE
Target $39
JEFF
Buy
Golden Entertainment recent shares weakness overdone, says Jefferies
Jefferies analyst David Katz says investor meetings with senior management of Golden Entertainment support his view that the shares are "among the most dislocated" in his coverage universe. While the company's Stratosphere in Las Vegas is exposed to near-term Las Vegas Strip volatility, it is also a long-term beneficiary of the fundamental strength, Katz tells investors in a research note titled "A Golden Opportunity." He says the hotel's $140M renovation is key to his investment thesis. The analyst also views Golden Entertainment's distributed business and forthcoming growth positively. Katz calls the recent weakness in shares of Golden Entertainment overdone and keeps a Buy rating on the name with a slightly reduced price target of $39.
10/05/18
DBAB
10/05/18
INITIATION
Target $40
DBAB
Buy
Golden Entertainment initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Danny Valoy last night initiated coverage of Golden Entertainment with a Buy rating and $40 price target. The analyst believes investments in the existing portfolio and a "solid" pipeline of acquisition targets across all business segments will continue to drive the company's growth. He believes the current 20% free cash flow yield represents a favorable risk/reward.
10/11/18
DBAB
10/11/18
NO CHANGE
DBAB
Buy
Golden Entertainment shares remain undervalued, says Deutsche Bank
Deutsche Bank analyst Danny Valoy left a meeting with Golden Entertainment management positive on the trajectory of the Stratosphere's renovation. He believes the property's gap to market opportunity, with RevPAR around 40% below the Las Vegas market and 50% below the Las Vegas Strip, could yield "significant EBITDA growth in time." Shares of Golden Entertainment remain undervalued, Valoy tells investors in a research note. He keeps a Buy rating on the name.
10/04/18
DBAB
10/04/18
INITIATION
DBAB
Buy
Golden Entertainment initiated with a Buy at Deutsche Bank
AKBA Akebia
$7.76

0.04 (0.52%)

08/23/18
HCWC
08/23/18
NO CHANGE
HCWC
Keryx, Akebia merger remains on track, says H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert believes the merger between Keryx Biopharmaceuticals (KERX) and Akebia Therapeutics (AKBA) remains on track. According to the Federal Trade Commission website, the status of the merger application now shows "granted," Kolbert tells investors in a research note. The analyst says that while he did not expect FTC clearance to be an issue, "it's good to see it granted." He keeps a Buy rating on Keryx with a $9 price target.
09/07/18
MSCO
09/07/18
INITIATION
Target $9
MSCO
Equal Weight
Akebia resumed with an Equal Weight at Morgan Stanley
Morgan Stanley analyst David Lebowitz resumed coverage of Akebia (AKBA) with an Equal Weight rating and $9 price target, stating that value is primarily driven by the potential of vadadustat as a treatment for anemia associated with chronic kidney disease. Vadadustat is a year behind FibroGen's (FGEN) competing HIF-inhibitor roxadustat and that lead could be an advantage if the data for the two drugs is not sufficiently differentiated, said Lebowitz.
11/12/18
11/12/18
DOWNGRADE

Market Perform
Raymond James downgrades Keryx to Market Perform ahead of Akebia deal closing
As previously reported, Raymond James analyst Reni Benjamin downgraded Keryx (KERX) to Market Perform from Outperform as he sees shares trading in-line with the market until the merger with Akebia (AKBA) is complete. The potential merger with Akebia is likely to go through by year-end, Benjamin contends. The merged company is likely to become "a fully-integrated renal powerhouse," the analyst added.
10/22/18
MZHO
10/22/18
NO CHANGE
Target $17
MZHO
Buy
Akebia 'significantly undervalued' ahead of catalysts, says Mizuho
Mizuho analyst Difei Yang views Akebia Therapeutics as "significantly undervalued" ahead of catalysts expected in 2019 including data readouts from vadadustat and launch metrics from Auryxia. The stock is one to pay attention to in 2019 following poor performance in 2018 "despite making progress in multiple pivotal trials," Yang tells investors in a research note. She lowered her price target for the shares to $17 from $21 and keeps a Buy rating on Akebia.
AMRS Amyris
$5.90

0.04 (0.68%)

06/26/18
HCWC
06/26/18
NO CHANGE
HCWC
Amyris partnership with BGI a positive, says H.C. Wainwright
H.C. Wainwright analyst Amit Dayal affirmed a Buy rating and $15 price target on Amyris, saying he believes the joint venture with Chinese genomics company BGI will further expand Amyris's international reach and will help Amyris enter into the multi-billion dollar Chinese medicine market.
08/30/18
HCWC
08/30/18
NO CHANGE
Target $15
HCWC
Buy
GRAS designation puts Amyris sweetener closer to launch, says H.C. Wainwright
After Amyris announced that its zero-calorie sweetener made from sugarcane received "Generally Recognized as Safe" designation from an independent panel, H.C. Wainwright analyst Amit Dayal said he believes this GRAS designation puts the product another step closer to a full commercial launch. The analyst, who sees the sweetener commercialization as a very important catalyst for Amyris, keeps a Buy rating and $15 price target on the stock.
10/03/18
HCWC
10/03/18
NO CHANGE
Target $15
HCWC
Buy
Amyris agreement with ASR brings 'significant' potential, says H.C. Wainwright
Amyris' supply agreement with ASR Group, the world's largest cane sugar refiner, brings "significant" revenue potential, H.C. Wainwright analyst Amit Dayal tells investors in a research note. The analyst believes Amyris is establishing supply relationships with key players in the sugar value chain who drive the adoption of new, consumer-friendly sweetener formulations. This strategy should allow the company to get maximum global distribution for every sweetener related end market from beverages to confectionery, contends Dayal. He reiterates a Buy rating on Amyris with a $15 price target.
03/20/18
RILY
03/20/18
NO CHANGE
Target $10
RILY
Buy
Amyris price target raised to $10 from $8 at B. Riley FBR
B. Riley FBR analyst Carter Driscoll raised his price target for Amyris to $10 and added the shares to his firm's Alpha Generator list. The analyst expects the commercial sweetener market to drive a back-half loaded year and positive earnings in 2019. Further, self-funding 2018 operations should quiet liquidity concerns, Driscoll tells investors in a research note. He keeps a Buy rating on Amyris.
QRHC Quest Resource
$2.23

-0.01 (-0.45%)

SWCH Switch
$9.27

-0.075 (-0.80%)

10/25/18
WELS
10/25/18
UPGRADE
Target $11.5
WELS
Outperform
Switch upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Jennifer Fritzsche upgraded Switch to Outperform while lowering her price target for the shares to $11.50 from $13.50. The analyst sees limited downside to the company's 2018 guidance given its "minimal churn." Further, Switch's growth poised to accelerate in 2019 and 2020, with favorable comps relative to 2018, Fritzsche tells investors in a research note. She believes the stock has "bottomed out" and views the current valuation as "compelling."
10/23/18
JEFF
10/23/18
INITIATION
Target $10
JEFF
Hold
Switch assumed with a Hold at Jefferies
Jefferies analyst Jonathan Petersen assumed coverage of Switch with a Hold rating while lowering his price target for the shares to $10 from $12. After the recent guidance reduction, Switch remains a "show me story" until it can demonstrate a path to consistent growth, Petersen tells investors in a research note.
08/14/18
08/14/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. CREDIT SUISSE INITIATES CASINO STOCKS: Credit Suisse analyst Cameron McKnight initiated Gaming and Leisure Properties (GLPI), VICI Properties (VICI), and PlayAGS (AGS) with an Outperform, Las Vegas Sands (LVS), Wynn Resorts (WYNN), MGM Growth (MGP), and International Game (IGT) with a Neutral, as well as Scientific Games (SGMS) with an Underperform. MORGAN STANLEY RAISES SALESFORCE PRICE TARGET TO $178 FROM $153: Morgan Stanley analyst Keith Weiss raised his price target for Salesforce (CRM) shares to $178 from $153 and maintained an Overweight rating. Weiss noted that unlocking data trapped in legacy systems via MuleSoft brings the company to the forefront of driving digital transformation for its customers and added that consensus expectations likely underestimate its growth potential as well as its improved track record in M&A. JEFFRIES SAYS "SIGNIFICANT SHAREHOLDER VALUE TO BE UNLOCKED" AT NIELSEN: Even following yesterday's 12% rally, there is "significant shareholder value to be unlocked" at Nielsen Holdings (NLSN), Jefferies analyst Surinder Thind told investors in a research note. Nielsen was also upgraded to Outperform from Neutral at Macquarie and to Equal Weight from Underweight at Barclays. Morgan Stanley analyst Toni Kaplan reiterated an Overweight rating and $26 price target on the stock. NOMURA RAISES PRICE TARGET AFTER SQUARE CASH APP SURPASSED PAYPAL'S VENMO IN JULY: Nomura Instinet analyst Dan Dolev raised his price target for Square (SQ) to $86 from $82 after his firm's July payments app tracker showed cumulative Square Cash App downloads surpassed PayPal's (PYPL) Venmo for the first time. SWITCH DOWNGRADED AT MULTIPLE FIRMS: Switch (SWCH) was downgraded to Market Perform from Outperform at Raymond James, to Neutral from Overweight at JPMorgan, and to Neutral from Buy at BTIG. Switch shares are down about 25% in morning trading.
08/14/18
08/14/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Chubb (CB) downgraded to Sell from Hold at Deutsche Bank with analyst Joshua Shanker saying the company's recent quarterly results show that Chubb, post-merger, is unable to grow its business at the levels of its peers. 2. Switch (SWCH) was downgraded to Market Perform from Outperform at Raymond James, to Neutral from Overweight at JPMorgan, and to Neutral from Buy at BTIG. 3. Urban Outfitters (URBN) downgraded to Neutral from Outperform at Baird with analyst Mark Altschwager citing valuation. 4. Premier (PINC) downgraded to Hold from Buy at Canaccord with analyst Richard Close citing its quarter-to-date outperformance. 5. Parker-Hannifin (PH) downgraded to Hold from Buy at Argus with analyst John Eade saying that while the company's recent Q4 results topped expectations, management's outlook for FY19 was worse than expected. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
WIX Wix.com
$91.30

2.83 (3.20%)

09/27/18
RHCO
09/27/18
NO CHANGE
Target $145
RHCO
Buy
Wix.com price target raised to $145 from $120 at SunTrust
SunTrust analyst Naved Khan raised his price target on Wix.com to $145 and kept his Buy rating, citing the positive results on Wix Code. The analyst notes that his survey of website designers indicates a "high level of awareness" for the Code product and the positive perception of its features, suggesting that Wix's go-to-market strategy has been successful. Khan adds that although the current usage of Code is small, the survey results suggest that its future adoption will grow, expanding the company's total addressable market.
10/10/18
KEYB
10/10/18
NO CHANGE
KEYB
Shopify, Salesforce should be bought on October pullback, says KeyBanc
KeyBanc analyst Brent Bracelin notes that the 55 largest SaaS stocks had an incredible run through the end of Q3, as the group benefited from robust secular tailwinds and multiple expansion with forward EV/S levels increasing by two full turns above the five-year average. That said, the "Big Chill" has quickly set in during the first nine days of October as the group is down 11% this month and 21% from the highs, on average, he adds. The analyst has identified eight high-quality SaaS stocks that he would buy on the October pullback based on attractive risk-reward and growth profiles looking out into 2020, namely Shopify (SHOP), Salesforce (CRM), Twilio (TWLO), Wix.com (WIX), Zendesk (ZEN), BlackLine (BL), Avalara (AVLR), and Mindbody (MB).
11/13/18
JEFF
11/13/18
NO CHANGE
Target $128
JEFF
Buy
Jefferies sees 'tough set-up' for Wix.com into Q3 results
Jefferies analyst Brent Thill sees a "tough set-up" for Wix.com (WIX) into the company's Q3 results with the shares up 55% year-to-date. Reaction to Q3 earnings reports has been poor in the sector, even in beat and raise scenarios, Thill tells investors in a pre-earnings research note. He points out that peer GoDaddy (GDDY) is down 13% since its Q3 report. The analyst thinks it is "prudent to be defensive" on GoDaddy into the print. Besides a "clean beat," Thill would like to see early positive signs for 2019 and "concrete monetization" plans for Code in Wix.com's quarter. He keeps a Buy rating on the shares with a $128 price target.
11/02/18
JPMS
11/02/18
NO CHANGE
JPMS
GoDaddy, Wix.com unaffected by VeriSign agreement, says JPMorgan
VeriSign (VRSN) last night announced that it reached an agreement with the Department of Commerce that gives the company the ability to once again raise prices on .com names by 7% max each of the last four years of its new six-year agreement, JPMorgan analyst Sterling Auty tells investors in a research note. This pricing flexibility is similar to what VeriSign had prior to 2012, the analyst adds. He believes that to the extent registrars can pass any price increases through to customers, like they did the last couple of price increases pre-2012, VeriSign's agreement should be a non-event to companies like GoDaddy (GDDY) and "definitely a non-event" to Wix.com (WIX), which he notes is not a registrar. However, if pricing in domains comes under pressure, any registry price increases could have an adverse effect on registrar gross margins like GoDaddy's (GDDY), says Auty.
TLRY Tilray
$111.25

-1.95 (-1.72%)

10/16/18
10/16/18
NO CHANGE
Target $200

Buy
Benchmark starts cannabis stock Tilray at Buy ahead of Canada legalizing
As previously reported, Benchmark analyst Mike Hickey initiated coverage of Tilray with a Buy rating and $200 price target, citing its early leadership in the medical cannabis market in Canada and the upcoming legalization of recreational cannabis, which begins in the North American nation tomorrow. He believes the company's strategic alliance with Novartis (NVS) and supply agreements with Canadian pharmacies that give Tilray a competitive edge in the Canadian medical cannabis market, Hickey tells investors. He also believes the potential international opportunity is "enormous," estimating that the global cannabis market opportunity could exceed $200B over the long-term. Hickey said Tilray is "well-positioned to take a meaningful share of this market."
11/06/18
COWN
11/06/18
NO CHANGE
COWN
Demand for adult use cannabis 'seemingly strong' in Canada, says Cowen
Citing her analysis of e-commerce platforms for adult use cannabis in Canada, Cowen analyst Vivien Azer remains encouraged to see "seemingly strong demand" as well as some instances of improved supply. In a research note pre-market open, the analyst notes she aggregated 533 product offerings with 1,149 SKUs from the e-commerce platforms for Alberta, British Columbia, Ontario, New Brunswick, and Newfoundland and Labrador. Overall, SKU stockout rates across the provinces were flat versus last week at 57%, although remains above the 46% rate during the prior week, Azer adds. Her view of the data is a modest positive for Canopy Growth (CGC), which has the second highest number of SKUs and out of stock rates declined from 65% to 54% while adding 16 SKUs this week. The read-through on Tilray (TLRY) is less clear, Azer contends, as the only three provinces where the company did not get supply agreements were all in her five province survey universe. The analyst reiterated an Outperform rating on Canopy Growth and Tilray.
11/07/18
ADAM
11/07/18
NO CHANGE
ADAM
Midterms broadly positive for U.S. cannabis industry, says Canaccord
Canaccord analyst Bobby Burleson says that as expected, yesterday's midterms delivered several wins for the U.S. cannabis industry, including the passage of three state ballot measures on legalization, key gubernatorial victories by pro-cannabis candidates, and the retaking of the House by Democrats. The analyst views these results as broadly positive for the U.S. cannabis industry. Publicly traded companies in the space include Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC) and Tilray (TLRY).
10/17/18
MSCO
10/17/18
NO CHANGE
MSCO
Morgan Stanley says pot legalization could pose risk to Canadian auto insurers
Morgan Stanley analyst Kai Pan noted that academic studies do not agree on the potential impact on car accidents from legalized recreational use of marijuana, but he still believes Canada's legalization could pose a risk to Canadian auto insurers. IFC, the largest auto insurer in Canada, is not immune to this challenge but given its long-term outperformance versus peers and strong claims management, Pan thinks the company should be better positioned in addressing this challenge, he tells investors. Publicly traded companies in the cannabis space include Aurora Cannabis (ACBFF), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC) and Tilray (TLRY).
APRN Blue Apron
$1.22

-0.03 (-2.40%)

02/16/18
02/16/18
UPGRADE

Neutral
Blue Apron upgraded to Neutral on retail partnership potential at Northcoast
As previously reported, Northcoast analyst Charles Cerankosky upgraded Blue Apron to Neutral from Sell. He noted that management is suggesting the company could be at breakeven EBITDA by year end, though he "is far less optimistic." Still, given the pressure of its negative cash flow, he thinks Blue Apron will explore a retail distribution partnership, which could have a potential headline benefit. However, Cerankosky added that he expects that even if such a retail distribution partnership was struck, he believes "disappointing sales at retail would likely force such a relationship to die quickly."
07/13/18
KEYB
07/13/18
NO CHANGE
KEYB
Sector Weight
Blue Apron's Costco test 'progressign well,' says KeyBanc
KeyBanc analyst Edward Yruma told investors in a research note that Blue Apron's (APRN) expansion of its on-demand meal kits at Costco (COST) continues to progress well, spreading to the Midwest and Southern areas of the U.S., and that this reinforces his increasingly constructive stance. While still small compared to direct-to-consumer, Yruma says the kits provide an opportunity for Blue Apron to conveniently reach new customers with a best-in-class national partner and that its upside prospects are becoming more favorable. Yruma maintains a Sector Weight rating, says valuation looks reasonable, and adds that operational issues at the Linden fulfillment centers are "largely in the past."
08/03/18
ADAM
08/03/18
NO CHANGE
Target $6
ADAM
Buy
Blue Apron downside risk limited at current levels, says Canaccord
Canaccord analyst Michael Graham noted Blue Apron reported mixed Q2 results and said the guidance suggests the revenue impact from the "transition" year will get worse in Q3 and Q4 before it gets better. Despite that, he sees reasons to be optimistic heading into 2019, including a likely return to intensive marketing and upside from nascent multi-channel offerings. Graham maintained his Buy rating and lowered his price target to $6 from $8 on Blue Apron shares.
10/05/18
KEYB
10/05/18
NO CHANGE
KEYB
Sector Weight
Blue Apron deal with GrubHub and one-time test provide flexibility, says KeyBanc
KeyBanc analyst Edward Yruma believes Blue Apron's (APRN) new partnership with GrubHub (GRUB) should provide a solid foundation for the launch of its on-demand meal kit offering and that its beta-test of its one-time delivery option on its own platform provides increased flexibility for customers. The analyst, who see the one-time delivery option as a unique offering, keeps a Sector Weight rating on Blue Apron shares.
RESN Resonant
$2.88

-0.03 (-1.03%)

08/10/18
LOOP
08/10/18
NO CHANGE
Target $11
LOOP
Buy
Loop Capital encouranged by Resonant development process
Loop Capital analyst Cody Acree kept his Buy rating and $11 price target on Resonant after its Q2 results despite the company's reduction of FY18 revenue growth target from mid-single-digit millions to low-single-digit millions. The analyst notes that the outlook change is mainly due to end-customer timing rather than the company's development delays, adding that he remains encouraged by Resonant's pace of progress.
09/21/18
HCWC
09/21/18
NO CHANGE
Target $8
HCWC
Buy
Resonant reaction to CFO change a buying opportunity, says H.C. Wainwright
H.C. Wainwright analyst Kevin Dede said that the exit of Mike Seifert from Resonant only weeks after he joined as the company's second-ever CFO on September 2 "may raise both red flags and hackles on the back of the neck," but he clearly does not agree with anyone suggesting that a worse case scenario is behind this morning's news. He attributes the company's hiring and subsequent loss of Siefert as being due to "poor due diligence and a seemingly rash decision," and notes that Jeff Killian, the company's original CFO now turned consultant, has returned to his old post until a committed replacement can be found. Dede, who would use the "knee jerk reaction" in the stock as an opportunity to enlarge an investment position, keeps a Buy rating and $8 price target on Resonant shares, which are down 5% to $4.15 in early trading.
06/21/18
LOOP
06/21/18
INITIATION
Target $11
LOOP
Buy
Resonant initiated with a Buy at Loop Capital
Loop Capital analyst Cody Acree initiated Resonant with a Buy rating and a price target of $11. The analyst cites the company's Infinite Synthesized Network platform technology - "a software-based, high-precision modeling approach that is able to produce real-world testable results in a completed design" which allows Resonant to eliminate design flaws in the software before wafer production begins. Acree believes that this approach will be much more "attractive to the market than the traditional method of running multiple physical iterations through a wafer fab".
04/04/18
CHLM
04/04/18
INITIATION
Target $7
CHLM
Buy
Resonant initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Anthony Stoss started Resonant with a Buy rating and $7 price target as he believes all the right pieces are in place and material volume and ASP improvements just around the corner.
CDNA CareDx
$25.49

-2.01 (-7.31%)

10/03/18
CHLM
10/03/18
NO CHANGE
Target $35
CHLM
Buy
CareDx price target raised to $35 from $20 at Craig-Hallum
Craig-Hallum analyst Per Ostlund raised his price target for CareDx to $35 from $20, while reiterating a Buy rating on the shares. With attractive reimbursement, strong early transplant center penetration and continued validation of dd-cfDNA as a biomarker to monitor organ allograft health, the analyst sees strong revenue growth continuing for the foreseeable future, while at the same time seeing significant leverage of this growth to the bottom line.
11/09/18
CHLM
11/09/18
NO CHANGE
Target $40
CHLM
Buy
CareDx price target raised to $40 from $35 at Craig-Hallum
Craig-Hallum analyst Per Ostlund reiterated a Buy rating on CareDX and raised his price target for shares to $40 from $35, telling investors in a research note that the company's results were "almost comically in excess" of his forecast. With nearly 100 transplant centers already using the test, K-OAR registry enrollment on track and continued early momentum, guidance was raised again, this time by $5.5M at the midpoint despite just one quarter left in the year, he says. Combining the AlloSure strength with continued mid-single digit volume growth in AlloMap, gains in the product business and the achievement of adjusted EBITDA profitability one quarter early, he says it is "difficult not to come away excited."
10/23/18
RAJA
10/23/18
INITIATION
Target $30
RAJA
Strong Buy
CareDx resumed with a Strong Buy at Raymond James
Raymond James analyst John Hsu resumed coverage on CareDx with a Strong Buy and $30 price target telling investors it has market leading products in non-invasive surveillance solutions for organ transplant recipients with robust revenue growth.
11/09/18
PIPR
11/09/18
NO CHANGE
Target $42
PIPR
Overweight
CareDx remains a top small cap idea at Piper Jaffray
Piper Jaffray analyst William Quirk says CareDx remains his top small cap idea following the company's Q3 beat and guidance raise. The beat was driven by "exceptional" AlloSure revenue growth of 106% year-over-year, Quirk tells investors in a post-earnings research note. He continue to believe CareDx is a "unique diagnostic asset" that is "poised for continued upside." The analyst keeps an Overweight rating on the stock with a $42 price target.
LADR Ladder Capital
$17.58

-0.03 (-0.17%)

03/27/18
RAJA
03/27/18
INITIATION
Target $17.5
RAJA
Strong Buy
Ladder Capital initiated with a Strong Buy at Raymond James
Raymond James initiated Ladder Capital with a Strong Buy and $17.50 price target.
04/18/18
RILY
04/18/18
NO CHANGE
Target $16
RILY
Buy
Ladder Capital selloff brings attractive entry point, says B. Riley FBR
B. Riley FBR analyst Tim Hayes says the recent selloff in shares of Ladder Capital creates an attractive entry point as the company's business remains fundamentally sound. The shares dropped 4% yesterday after Related Fund Management withdrew its proposal to acquire the company. Hayes trimmed his price target for Ladder shares to $16 from $16.50 and reiterates a Buy rating on the name.
05/30/18
RILY
05/30/18
NO CHANGE
Target $16
RILY
Buy
Ladder Capital dividend raise may not be last of 2018, says B. Riley FBR
B. Riley FBR analyst Tim Hayes says Ladder Capital's 3% dividend raise today follows the company's "record" Q1 results and may not be the last one of 2018. The analyst keeps a Buy rating on the shares with a $16 price target.
10/24/18
JPMS
10/24/18
DOWNGRADE
Target $18
JPMS
Neutral
Ladder Capital downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Richard Shane downgraded Ladder Capital to Neutral with an unchanged price target of $18. The analyst cites valuation for the downgrade, saying the year-to-date outperformance has brought the stock close to his target. He sees "limited additional upside."
ED Consolidated Edison
$79.14

0.48 (0.61%)

11/05/18
EVER
11/05/18
UPGRADE
Target $74
EVER
In Line
Consolidated Edison upgraded to In Line on valuation at Evercore ISI
Evercore ISI analyst Greg Gordon upgraded Consolidated Edison to In Line from Underperform citing valuation and maintained a $74 price target.
11/05/18
GSCO
11/05/18
UPGRADE
GSCO
Neutral
Consolidated Edison upgraded to Neutral from Sell at Goldman Sachs
07/24/18
HOWW
07/24/18
INITIATION
Target $73
HOWW
Underperform
Consolidated Edison reinstated with an Underperform at Scotia Howard Weil
Scotia Howard Weil analyst Andrew Weisel reinstated Consolidated Edison with a Underperform and $32.
11/06/18
GSCO
11/06/18
UPGRADE
Target $73
GSCO
Neutral
Consolidated Edison upgraded to Neutral with $73 target at Goldman Sachs
Goldman Sachs analyst Michael Lapides last night upgraded Consolidated Edison to Neutral from Sell and raised his price target for the shares to $73 from $72. The analyst is more positive on the shares following the underperformance in 2018. Further, to reflect improved regulated earnings and renewable growth in 2019, Lapides slightly increased his long-term estimates for Consolidated Edison.

TODAY'S FREE FLY STORIES

BHVN

Biohaven Pharmaceutical

$37.72

1.02 (2.78%)

20:51
12/12/18
12/12
20:51
12/12/18
20:51
Syndicate
Biohaven Pharmaceutical 3.3M share Secondary priced at $37.25 per share »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

FIVE

Five Below

$101.38

1.86 (1.87%)

20:48
12/12/18
12/12
20:48
12/12/18
20:48
Upgrade
Five Below rating change at Goldman Sachs »

Five Below upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRNS

Marinus Pharmaceuticals

$4.21

-0.89 (-17.45%)

20:28
12/12/18
12/12
20:28
12/12/18
20:28
Syndicate
Marinus Pharmaceuticals 12M share Secondary priced at $3.75 per share »

Jefferies and Leerink are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

UNM

Unum Group

$30.27

-0.04 (-0.13%)

20:25
12/12/18
12/12
20:25
12/12/18
20:25
Hot Stocks
Unum Group sees FY19 adjusted EPS growth of 4%-7% »

Sees FY19 tax rate of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CIEN

Ciena

$32.14

0.535 (1.69%)

20:25
12/12/18
12/12
20:25
12/12/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

TDC

Teradata

$38.02

0.65 (1.74%)

20:18
12/12/18
12/12
20:18
12/12/18
20:18
Hot Stocks
Teradata targets 2021 recurring revenue growth of 14% »

Also sees 2021 gross…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 19

    Dec

  • 20

    Dec

HESM

Hess Midstream Partners

$19.43

0.38 (1.99%)

19:09
12/12/18
12/12
19:09
12/12/18
19:09
Hot Stocks
Hess Midstream Partners sees FY19 adjusted EBITDA $550M-$575M »

Sees FY19: net income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOCA

Tocagen

$11.22

-1.63 (-12.68%)

19:05
12/12/18
12/12
19:05
12/12/18
19:05
Syndicate
Tocagen 3M share Secondary priced at $10.00 per share »

Citi and Leerink are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

ALL

Allstate

$82.37

-0.12 (-0.15%)

19:03
12/12/18
12/12
19:03
12/12/18
19:03
Hot Stocks
Allstate announces estimated November catastrophe losses of $685M »

Allstate announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$76.04

-0.64 (-0.83%)

19:01
12/12/18
12/12
19:01
12/12/18
19:01
Hot Stocks
Exxon makes final investment decision to develop West Barracouta gas project »

ExxonMobil said that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDSN

Nordson

$111.83

1.09 (0.98%)

, JCS

Communications Systems

$2.42

0.2 (9.01%)

19:00
12/12/18
12/12
19:00
12/12/18
19:00
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

NDSN

Nordson

$111.83

1.09 (0.98%)

JCS

Communications Systems

$2.42

0.2 (9.01%)

BW

Babcock & Wilcox

$0.77

0.0569 (7.94%)

FIVE

Five Below

$101.38

1.86 (1.87%)

BABA

Alibaba

$151.49

-0.34 (-0.22%)

TLRD

Tailored Brands

$20.16

0.32 (1.61%)

LLNW

Limelight Networks

$3.20

0.025 (0.79%)

OXM

Oxford Industries

$74.88

0.895 (1.21%)

AGTC

Applied Genetic

$6.61

0.54 (8.90%)

VBIV

VBI Vaccines

$1.66

0.08 (5.06%)

HASI

Hannon Armstrong

$23.10

-0.16 (-0.69%)

BVN

Buenaventura

$15.25

0.22 (1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 13

    Dec

  • 04

    Mar

  • 12

    Mar

  • 13

    Dec

  • 13

    Dec

OXM

Oxford Industries

$74.88

0.895 (1.21%)

18:58
12/12/18
12/12
18:58
12/12/18
18:58
Earnings
Oxford Industries cuts FY18 EPS view to $4.20-$4.35 from $4.45-$4.65 »

Cuts FY18 revenue view to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

OXM

Oxford Industries

$74.88

0.895 (1.21%)

18:56
12/12/18
12/12
18:56
12/12/18
18:56
Earnings
Oxford Industries sees Q4 EPS 96c-$1.11 vs. 93c last year »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

OXM

Oxford Industries

$74.88

0.895 (1.21%)

18:55
12/12/18
12/12
18:55
12/12/18
18:55
Earnings
Oxford Industries reports Q3 adjusted EPS 14c vs. 17c last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

NEXT

NextDecade

$4.74

0.04 (0.85%)

18:30
12/12/18
12/12
18:30
12/12/18
18:30
Hot Stocks
NextDecade's Rio Grande LNG project approved by TCEQ »

NextDecade Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$89.63

1.49 (1.69%)

18:15
12/12/18
12/12
18:15
12/12/18
18:15
Periodicals
United CEO seeks to boost flight network by 4%-6% next year, Reuters says »

United Airlines CEO Oscar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

AKAO

Achaogen

$1.80

0.06 (3.45%)

17:58
12/12/18
12/12
17:58
12/12/18
17:58
Hot Stocks
Breaking Hot Stocks news story on Achaogen »

Robert Duggan raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLR

Fluor

$34.11

0.29 (0.86%)

17:56
12/12/18
12/12
17:56
12/12/18
17:56
Hot Stocks
Fluor announces participation in $2.1B rail project in Chicago »

Fluor announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIVE

Five Below

$101.38

1.86 (1.87%)

17:55
12/12/18
12/12
17:55
12/12/18
17:55
Upgrade
Five Below rating change at Goldman Sachs »

Five Below upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTC

Bitcoin

$0.00

(0.00%)

, BITCOIN

Bitcoin

$0.00

(0.00%)

17:49
12/12/18
12/12
17:49
12/12/18
17:49
Hot Stocks
SEC says former execs behind allegedly fraudulent ICO settle scam charges »

Two former executives…

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PK

Park Hotels & Resorts

$29.28

0.08 (0.27%)

17:44
12/12/18
12/12
17:44
12/12/18
17:44
Hot Stocks
Park Hotels & Resorts announces Q4 dividend of $1.00 per share »

Park Hotels & Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PK

Park Hotels & Resorts

$29.28

0.08 (0.27%)

17:44
12/12/18
12/12
17:44
12/12/18
17:44
Hot Stocks
Park Hotels & Resorts announces Q4 dividend of $1.00 per share »

Park Hotels & Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNP

CenterPoint Energy

$28.90

0.12 (0.42%)

17:37
12/12/18
12/12
17:37
12/12/18
17:37
Hot Stocks
CenterPoint Energy raises dividend 4% to 28.75c per share »

The company's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPLD

Upland Software

$27.47

0.51 (1.89%)

17:34
12/12/18
12/12
17:34
12/12/18
17:34
Syndicate
Breaking Syndicate news story on Upland Software »

Upland Software files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

  • 20

    Dec

GNTY

Guaranty Bancshares

$29.78

0.13 (0.44%)

17:32
12/12/18
12/12
17:32
12/12/18
17:32
Syndicate
Breaking Syndicate news story on Guaranty Bancshares »

Guaranty Bancshares files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.